Connor, Clark & Lunn Investment Management Ltd. Alx Oncology Holdings Inc Transaction History
Connor, Clark & Lunn Investment Management Ltd.
- $21.8 Billion
- Q1 2024
A detailed history of Connor, Clark & Lunn Investment Management Ltd. transactions in Alx Oncology Holdings Inc stock. As of the latest transaction made, Connor, Clark & Lunn Investment Management Ltd. holds 29,084 shares of ALXO stock, worth $166,360. This represents 0.0% of its overall portfolio holdings.
Number of Shares
29,084
Previous 13,309
118.53%
Holding current value
$166,360
Previous $198,000
63.64%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding ALXO
# of Institutions
115Shares Held
38.4MCall Options Held
132KPut Options Held
19.7K-
Ven Bio Partners LLC San Francisco, CA9.7MShares$55.5 Million42.27% of portfolio
-
Redmile Group, LLC San Francisco, CA4.33MShares$24.7 Million1.9% of portfolio
-
Vivo Capital, LLC Palo Alto, CA4.22MShares$24.1 Million6.29% of portfolio
-
Cormorant Asset Management, LP Boston, MA3.14MShares$18 Million2.02% of portfolio
-
Orbimed Advisors LLC San Diego, CA2.72MShares$15.5 Million0.68% of portfolio
About ALX ONCOLOGY HOLDINGS INC
- Ticker ALXO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 40,747,100
- Market Cap $233M
- Description
- ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hod...